













- fibroblasts in metastatic cancer patients,” *BMC Cancer*, vol. 20, no. 1, pp. 1–13, 2020, doi: 10.1186/s12885-020-07376-1.
- [9] R. S. Epstein *et al.*, “Cancer patients’ perspectives and experiences of chemotherapy-induced myelosuppression and its impact on daily life,” *Patient Prefer. Adherence*, vol. 15, pp. 453–465, 2021, doi: 10.2147/PPA.S292462.
- [10] S. S. Arunachalam *et al.*, “Study on knowledge of chemotherapy’s adverse effects and their self-care ability to manage - The cancer survivors impact,” *Clin. Epidemiol. Glob. Heal.*, vol. 11, no. March, p. 100765, 2021, doi: 10.1016/j.cegh.2021.100765.
- [11] B. Prieto-Callejero *et al.*, “Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer,” *Medicine (Baltimore)*, vol. 99, no. 33, p. e21695, 2020, doi: 10.1097/MD.00000000000021695.
- [12] M. Mansour, S. Ismail, and K. Abou-Aisha, “Bacterial delivery of the antitumor azurin-like protein Laz to glioblastoma cells,” *AMB Express*, vol. 10, no. 1, 2020, doi: 10.1186/s13568-020-00995-8.
- [13] D. Trivanović, K. Pavelić, and Ž. Peršurić, “Fighting Cancer with Bacteria and Their Toxins,” *Int. J. Mol. Sci.*, vol. 22, no. 23, 2021, doi: 10.3390/ijms222312980.
- [14] M. Sedighi *et al.*, “Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities,” *Cancer Med.*, vol. 8, no. 6, pp. 3167–3181, 2019, doi: 10.1002/cam4.2148.
- [15] M. T. Q. Duong, Y. Qin, S. H. You, and J. J. Min, “Bacteria-cancer interactions: bacteria-based cancer therapy,” *Exp. Mol. Med.*, vol. 51, no. 12, 2019, doi: 10.1038/s12276-019-0297-0.
- [16] X. Zhang, X. Hu, and X. Rao, “Apoptosis induced by *Staphylococcus aureus* toxins,” *Microbiol. Res.*, vol. 205, no. April, pp. 19–24, 2017, doi: 10.1016/j.micres.2017.08.006.
- [17] K. E. J. Rödström, K. Elbing, and K. Lindkvist-Petersson, “Structure of the Superantigen Staphylococcal Enterotoxin B in Complex with TCR and Peptide–MHC Demonstrates Absence of TCR–Peptide Contacts,” *J. Immunol.*, vol. 193, no. 4, pp. 1998–2004, 2014, doi: 10.4049/jimmunol.1401268.
- [18] P. Knopick *et al.*, “Endogenous HLA-DQ8 $\alpha\beta$  programs superantigens (SEG/SEI) to silence toxicity and unleash a tumoricidal network with long-term melanoma survival,” *J. Immunother. Cancer*, vol. 8, no. 2, 2020, doi: 10.1136/jitc-2020-001493.
- [19] D. Verreault *et al.*, “Effective treatment of staphylococcal enterotoxin B aerosol intoxication in rhesus macaques by using two parenterally administered high-affinity monoclonal antibodies,” *Antimicrob. Agents Chemother.*, vol. 63, no. 5, pp. 1–12, 2019, doi: 10.1128/AAC.02049-18.
- [20] D. M. Ranelli, C. L. Jones, M. B. Johns, G. J. Mussey, and S. A. Khan, “Molecular cloning of staphylococcal enterotoxin B gene in *Escherichia coli* and *Staphylococcus aureus*,” *Proc. Natl. Acad. Sci. U. S. A.*, vol. 82, no. 17, pp. 5850–5854, 1985, doi: 10.1073/pnas.82.17.5850.
- [21] J. W. Dubendorf and F. W. Studier, “Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor,” *J. Mol. Biol.*, vol. 219, no. 1, pp. 45–59, 1991, doi: [https://doi.org/10.1016/0022-2836\(91\)90856-2](https://doi.org/10.1016/0022-2836(91)90856-2).
- [22] C. Ye, X. Chen, M. Yang, X. Zeng, and S. Qiao, “CRISPR/Cas9 mediated T7 RNA polymerase gene knock-in in *E. coli* BW25113 makes T7 expression system work efficiently,” *J. Biol. Eng.*, vol. 15, no. 1, pp. 1–16, 2021, doi: 10.1186/s13036-021-00270-9.
- [23] P. J. Shilling, K. Mirzadeh, A. J. Cumming, M. Widesheim, Z. Köck, and D. O. Daley, “Improved designs for pET expression plasmids increase protein production yield in *Escherichia coli*,” *Commun. Biol.*, vol. 3, no. 1, 2020, doi: 10.1038/s42003-020-0939-8.
- [24] M. J. Park, M. S. Park, and G. E. Ji, “Improvement of the electro-transformed cell yield for *Bifidobacterium* sp. With large DNA,” *Korean J. Food Sci. Technol.*, vol. 51, no. 2, pp. 188–191, 2019, doi: 10.9721/KJFST.2019.51.2.188.
- [25] M. M. Islam *et al.*, “Cell-Penetrating Peptide-Mediated Transformation of Large Plasmid DNA into *Escherichia coli*,” *ACS Synth. Biol.*, vol. 8, no. 5, pp. 1215–1218, 2019, doi: 10.1021/acssynbio.9b00055.
- [26] Y. Wang *et al.*, “Effects of Sr<sup>2+</sup> on the preparation of *Escherichia coli* DH5 $\alpha$  competent cells and plasmid transformation,” *PeerJ*, vol. 8, p. e9480, 2020.
- [27] S. B. Nouemssi, M. Ghribi, R. Beauchemin, F. Meddeb-Mouelhi, H. Germain, and I. Desgagné-Penix, “Rapid and efficient colony-pcr for high throughput screening of genetically transformed *Chlamydomonas reinhardtii*,” *Life*, vol. 10, no. 9, pp. 1–13, 2020, doi: 10.3390/life10090186.
- [28] M. R. Green and J. Sambrook, “Polymerase chain reaction,” *Cold Spring Harb. Protoc.*, vol. 2019, no. 6, p. pdb-top095109, 2019.
- [29] Z. J. Johnson, D. D. Krutkin, P. Bohutskyi, and M. G. Kalyuzhnaya, “Metals and methylotrophy: Via global gene expression studies,” *Methods Enzymol.*, vol. 650, pp. 185–213, Jan. 2021, doi: 10.1016/BS.MIE.2021.01.046.
- [30] C. Delahaye and J. Nicolas, “Sequencing DNA with nanopores: Troubles and biases,” *PLoS One*, vol. 16, no. 10 October, 2021, doi: 10.1371/journal.pone.0257521.
- [31] A. Alexaki *et al.*, “Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies,” *Sci. Rep.*, vol. 9, no. 1, 2019, doi: 10.1038/s41598-019-51984-2.
- [32] Y. Liu, “A code within the genetic code: Codon usage regulates co-translational protein folding,” *Cell Commun. Signal.*, vol. 18, no. 1, pp. 1–9, 2020, doi: 10.1186/s12964-020-00642-6.
- [33] F. Xue *et al.*, “Codon-Optimized *Rhodotorula glutinis* PAL Expressed in *Escherichia coli* With Enhanced Activities,” *Front. Bioeng. Biotechnol.*, vol. 8, no. February, pp. 1–9, 2021, doi: 10.3389/fbioe.2020.610506.
- [34] J. Konczal, J. Bower, and C. H. Gray, “Re-introducing non-optimal synonymous codons into codon-optimized constructs enhances soluble recovery of recombinant proteins from *Escherichia coli*,” *PLoS One*, vol. 14, no. 4, pp. 1–17, 2019, doi: 10.1371/journal.pone.0215892.
- [35] H. Fu *et al.*, “Codon optimization with deep learning to enhance protein expression,” *Sci. Rep.*, vol. 10, no. 1, pp. 1–9, 2020, doi: 10.1038/s41598-020-74091-z.
- [36] N. I. M. Nik-Pa *et al.*, “Combined optimization of codon usage and glycine supplementation enhances the extracellular production of a  $\beta$ -cyclodextrin glycosyltransferase from *Bacillus* sp. Nr5 upm in *Escherichia coli*,” *Int. J. Mol. Sci.*, vol. 21, no. 11, 2020, doi: 10.3390/ijms211113919.
- [37] G. L. Rosano, E. S. Morales, and E. A. Ceccarelli, “New tools for recombinant protein production in *Escherichia coli*: A 5-year update,” *Protein Sci.*, vol. 28, no. 8, pp. 1412–1422, 2019, doi: 10.1002/pro.3668.
- [38] S. Mahmoodi, M. Pourhassan-Moghaddam, D. W. Wood, H. Majdi, and N. Zarghami, “Current affinity approaches for purification of recombinant proteins,” *Cogent Biol.*, vol. 5, no. 1, p. 1665406, 2019, doi: 10.1080/23312025.2019.1665406.
- [39] A. Bhatwa, W. Wang, Y. I. Hassan, N. Abraham, X. Z. Li, and T. Zhou, “Challenges Associated With the Formation of Recombinant Protein Inclusion Bodies in *Escherichia coli* and Strategies to Address Them for Industrial Applications,” *Frontiers in Bioengineering and Biotechnology*, vol. 9, no. February, pp. 1–18, 2021, doi: 10.3389/fbioe.2021.630551.
- [40] R. Agrawal, P. K. Singh, S. K. Sharma, D. V. Kamboj, A. K. Goel, and L. Singh, “Highly Expressed Recombinant SEB for Antibody Production and Development of Immunodetection System,” *Indian J. Microbiol.*, vol. 52, no. 2, pp. 191–196, 2012, doi: 10.1007/s12088-011-0173-7.